08.19.25 -- As Billions Of Dollars Pour In, Do CDMO Valuations Matter?

Join Outsourced Pharma Online on September 3rd at 2pm ET for a virtual panel discussion on overcoming difficulties outsourcing development and manufacturing, how does a biopharma organization (of any size) handle a multi-CDMO coordination. Registration is free for this digital event.

Findings provide critical insights into refining ASO extraction protocols, which can enhance the accuracy of downstream analyses and support further research into ASO-based therapeutics.

Explore essential QC strategies in AAV gene therapy and learn how to address rcAAV detection, viral clearance per ICH Q5A, and impurity profiling using NGS to meet evolving regulatory demands.

Explore how a platform compares data to traditional qPCR, p24 ELISA, and TU assays in measuring both physical and functional titers.

Following recent news about first-in-human testing, two executives discuss the science and manufacturing strategy for the company's lead candidate, ABO-101.

With experience in managing assay transfers across diverse sources and development stages, we have identified five factors that can significantly impact the success of potency assay transfers.

Protect the integrity of your therapies and ensure patient safety by investing in reliable, real-time environmental monitoring systems that proactively address operational vulnerabilities.

Discover how our innovative rAAV production platform can revolutionize your gene therapy pipeline with unparalleled yield, quality, and scalability.

Examine how a partner with extensive capabilities and expertise adds value to drug development and helps to solve complex formulation, analytical, and manufacturing challenges our clients face.

This study aims to explore the kinetics of capsid formation and impurity profiles over time, offering insights that can inform future process improvements.

Learn how to navigate decision-making at critical steps and find solutions to key challenges in process development and scale-up to expedite oncolytic virus programs.

Listen as Mike Dybicz, SVP and Chief Product Development Officer, shares how HV3 and Safepak innovations are transforming CGT logistics to ensure safe and reliable delivery.

Using cells with a pre-engineered TARGATT™ landing pad, we achieve inducible expression within just 4-6 weeks after donor plasmid creation, significantly reducing development time and effort.

Let us support your high-quality medicines with integrated offerings in mammalian drug substances and drug products, including our fill and finish services for vials, syringes, cartridges, and auto-injectors.

Discover a one-stop-shop for LNP technologies that provides access to expertise in formulation and analytics for successful outcomes for payload and target applications.

With a simple quote and 10 mg of your research grade transgene plasmid, we can perform a small scale feasibility study, including downstream purification.

By combining technical excellence with a passion for progress, we enable our customers to bring life-changing therapies to market efficiently and reliably.

Synergy between analytical development and quality control teams enables manufacturing processes that adhere strictly to the highest regulatory standards, fostering trust and reliability.